UiPath Inc. (NYSE:PATH) Receives $17.94 Average PT from Analysts

UiPath Inc. (NYSE:PATH) has been given a consensus recommendation of “Hold” by the eighteen research firms that are covering the firm, Marketbeat.com reports. Sixteen investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $17.71.

Several equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. decreased their target price on shares of UiPath from $28.00 to $19.00 and set an “overweight” rating for the company in a research note on Thursday, May 30th. Scotiabank decreased their price objective on UiPath from $30.00 to $25.00 and set a “sector perform” rating for the company in a research report on Wednesday, May 29th. Barclays lifted their target price on UiPath from $14.00 to $15.00 and gave the company an “equal weight” rating in a research note on Friday, September 6th. DA Davidson upped their price target on UiPath from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Friday, September 6th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $16.00 price objective on shares of UiPath in a research report on Friday, September 6th.

UiPath Stock Down 1.4 %

NYSE:PATH opened at $12.02 on Friday. UiPath has a 52-week low of $10.37 and a 52-week high of $27.87. The stock’s 50 day moving average price is $12.17 and its 200 day moving average price is $16.46. The company has a market capitalization of $6.88 billion, a PE ratio of -75.13 and a beta of 0.87.

UiPath (NYSE:PATH) last announced its earnings results on Thursday, September 5th. The healthcare company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01. The business had revenue of $316.00 million for the quarter, compared to analysts’ expectations of $303.69 million. UiPath had a negative net margin of 8.13% and a negative return on equity of 3.89%. The company’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.09) EPS. As a group, sell-side analysts anticipate that UiPath will post -0.22 EPS for the current fiscal year.

Institutional Investors Weigh In On UiPath

A number of hedge funds and other institutional investors have recently modified their holdings of PATH. Norges Bank acquired a new stake in shares of UiPath in the 4th quarter worth approximately $165,749,000. Pacer Advisors Inc. acquired a new stake in UiPath in the second quarter valued at $69,180,000. Vanguard Group Inc. increased its position in shares of UiPath by 5.6% in the first quarter. Vanguard Group Inc. now owns 40,217,936 shares of the healthcare company’s stock valued at $911,741,000 after buying an additional 2,133,078 shares in the last quarter. Artisan Partners Limited Partnership acquired a new position in shares of UiPath during the 4th quarter worth $48,267,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of UiPath in the 2nd quarter worth about $13,280,000. 62.50% of the stock is currently owned by institutional investors and hedge funds.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.